Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Type 2 diabetes
Biotech
Novo CEO accepts ‘couple of setbacks,’ hunts for bolt-on deals
Novo Nordisk’s CEO admitted the pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular drug ziltivekimab.
James Waldron
Aug 5, 2026 8:00am
ADA: Novo CSO says ‘jury still out’ on CagriSema v. retatrutide
Jun 10, 2026 11:10am
ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2
Jun 9, 2026 9:48am
ADA: Dexcom CGM shows benefit in non-insulin diabetes patients
Jun 8, 2026 11:15am
ADA: Lilly offers deeper glimpse into triple-G obesity candidate
Jun 6, 2026 3:28pm
ADA: Pfizer pads case for berobenatide in obesity
Jun 6, 2026 9:29am
